摘要
急性淋巴细胞白血病(acute lymphoblastic leukemia,ALL)是一组高度异质性的来源于淋巴前体细胞的血液系统恶性克隆性肿瘤。近些年随着危险分层治疗体系的完善及酪氨酸激酶抑制剂、单克隆抗体、嵌合抗原受体T细胞、其它靶向药物等新药的出现,ALL的治疗效果得到了大幅度的提高,本文就ALL的诊疗规范及最新研究进展等有关内容进行简述。
Acute lymphoblastic leukemia(ALL)is a highly heterogeneous hematological malignancy resulting from clonal proliferation of lymphoid precursor cells.In recent years,with the optimization of risk stratification model and the emergence of new drugs,such as tyrosine kinase inhibitors,monoclonal antibodies,chimeric antigen receptor T cells and other targeted drugs,the outcomes of ALL patients have been greatly improved.This article briefly described the current standards for treatment of ALL.Also,the latest progress in the therapy of ALL were discussed.
作者
卢文艺
赵明峰
Lu Wenyi;Zhao Mingfeng(Department of Hematology, Tianjin First Central Hospital, First Affiliated Central Hospital of Nankai University, Tianjin Medical Key Construction Subject Internal Medicine (Hematology), Tianjin 300192, China)
出处
《临床荟萃》
CAS
2021年第10期874-879,共6页
Clinical Focus
基金
天津市医学重点学科建设项目。
关键词
白血病
淋巴组织
分子靶向治疗
抗体
单克隆
leukemia
lymphoid tissue
molecular targeted therapy
antibodies,monoclonal
